Astrazeneca (AZN) Receivables - Net (2016 - 2025)
Astrazeneca has reported Receivables - Net over the past 11 years, most recently at $15.2 billion for Q4 2025.
- Quarterly results put Receivables - Net at $15.2 billion for Q4 2025, up 17.0% from a year ago — trailing twelve months through Dec 2025 was $15.2 billion (up 17.0% YoY), and the annual figure for FY2025 was $15.2 billion, up 17.0%.
- Receivables - Net for Q4 2025 was $15.2 billion at Astrazeneca, up from $13.0 billion in the prior quarter.
- Over the last five years, Receivables - Net for AZN hit a ceiling of $15.2 billion in Q4 2025 and a floor of $7.2 billion in Q4 2022.
- Median Receivables - Net over the past 5 years was $9.6 billion (2021), compared with a mean of $10.7 billion.
- Biggest five-year swings in Receivables - Net: fell 25.22% in 2022 and later surged 54.3% in 2024.
- Astrazeneca's Receivables - Net stood at $9.6 billion in 2021, then fell by 25.22% to $7.2 billion in 2022, then increased by 16.57% to $8.4 billion in 2023, then surged by 54.3% to $13.0 billion in 2024, then increased by 17.0% to $15.2 billion in 2025.
- The last three reported values for Receivables - Net were $15.2 billion (Q4 2025), $13.0 billion (Q4 2024), and $8.4 billion (Q4 2023) per Business Quant data.